Splash Beverage Acquires Exclusive Global Rights for Epilepsy Therapy CannEpil

MT Newswires Live07-06

Splash Beverage (SBEV) said Monday it has signed an agreement with Argent BioPharma to acquire exclusive global licensing for an initial 20-year term for CannEpil, a cannabinoid-based investigational therapeutic for the treatment of drug-resistant epilepsy.

As part of the deal, Splash has secured a $1 million commitment from C/M Capital Partners to fund the development of CannEpil in the US and other key markets, the company said.

Mercer Street Global Opportunity Fund has also agreed to forgive about $5 million of Argent BioPharma indebtedness and Splash has agreed to issue $5.5 million of newly issued Splash preferred equity.

Splash said that Argent BioPharma is further incentivized to take part in the CannEpil program through a royalty equal to 15% of net revenue generated from worldwide sales of CannEpil.

CannEpil is currently available in multiple international markets like Ireland, the United Kingdom, Germany and Australia, the company added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649624454?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649624454","market":"us","top_or_hot":-1,"title":"Splash Beverage Acquires Exclusive Global Rights for Epilepsy Therapy CannEpil","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SBEV\">Splash Beverage</a> (SBEV) said Monday it has signed an agreement with <a href=\"https://laohu8.com/S/RGTLF\">Argent BioPharma</a> to acquire exclusive global licensing for an initial 20-year term for CannEpil, a cannabinoid-based investigational therapeutic for the treatment of drug-resistant epilepsy.</p><p>As part of the deal, Splash has secured a $1 million commitment from C/M Capital Partners to fund the development of CannEpil in the US and other key markets, the company said.</p><p>Mercer Street Global Opportunity Fund has also agreed to forgive about $5 million of <a href=\"https://laohu8.com/S/RGT.AU\">Argent BioPharma</a> indebtedness and Splash has agreed to issue $5.5 million of newly issued Splash preferred equity.</p><p>Splash said that Argent BioPharma is further incentivized to take part in the CannEpil program through a royalty equal to 15% of net revenue generated from worldwide sales of CannEpil.</p><p>CannEpil is currently available in multiple international markets like Ireland, the United Kingdom, Germany and Australia, the company added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Splash Beverage Acquires Exclusive Global Rights for Epilepsy Therapy CannEpil</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSplash Beverage Acquires Exclusive Global Rights for Epilepsy Therapy CannEpil\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-06 21:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SBEV\">Splash Beverage</a> (SBEV) said Monday it has signed an agreement with <a href=\"https://laohu8.com/S/RGTLF\">Argent BioPharma</a> to acquire exclusive global licensing for an initial 20-year term for CannEpil, a cannabinoid-based investigational therapeutic for the treatment of drug-resistant epilepsy.</p><p>As part of the deal, Splash has secured a $1 million commitment from C/M Capital Partners to fund the development of CannEpil in the US and other key markets, the company said.</p><p>Mercer Street Global Opportunity Fund has also agreed to forgive about $5 million of <a href=\"https://laohu8.com/S/RGT.AU\">Argent BioPharma</a> indebtedness and Splash has agreed to issue $5.5 million of newly issued Splash preferred equity.</p><p>Splash said that Argent BioPharma is further incentivized to take part in the CannEpil program through a royalty equal to 15% of net revenue generated from worldwide sales of CannEpil.</p><p>CannEpil is currently available in multiple international markets like Ireland, the United Kingdom, Germany and Australia, the company added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SBEV","symbol_name":"Splash Beverage Group Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2649624454","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649624454","pubTimestamp":1783343871,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Splash Beverage  said Monday it has signed an agreement with Argent BioPharma to acquire exclusive global licensing for an initial 20-year term for CannEpil, a cannabinoid-based investigational therapeutic for the treatment of drug-resistant epilepsy.As part of the deal, Splash has secured a $1 million commitment from C/M Capital Partners to fund the development of CannEpil in the US and other key markets, the company said.Mercer Street Global Opportunity Fund has also agreed to forgive about $5 million of Argent BioPharma indebtedness and Splash has agreed to issue $5.5 million of newly issued Splash preferred equity.Splash said that Argent BioPharma is further incentivized to take part in the CannEpil program through a royalty equal to 15% of net revenue generated from worldwide sales of CannEpil.CannEpil is currently available in multiple international markets like Ireland, the United Kingdom, Germany and Australia, the company added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SBEV":"Splash Beverage Group Inc.","BK4169":"酿酒商与葡萄酒商","BK4113":"食品零售"},"translate_title":"Splash Beverage获得癫痫疗法CannEpil的全球独家权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SBEV":1},"content_text":"Splash Beverage (SBEV) said Monday it has signed an agreement with Argent BioPharma to acquire exclusive global licensing for an initial 20-year term for CannEpil, a cannabinoid-based investigational therapeutic for the treatment of drug-resistant epilepsy.As part of the deal, Splash has secured a $1 million commitment from C/M Capital Partners to fund the development of CannEpil in the US and other key markets, the company said.Mercer Street Global Opportunity Fund has also agreed to forgive about $5 million of Argent BioPharma indebtedness and Splash has agreed to issue $5.5 million of newly issued Splash preferred equity.Splash said that Argent BioPharma is further incentivized to take part in the CannEpil program through a royalty equal to 15% of net revenue generated from worldwide sales of CannEpil.CannEpil is currently available in multiple international markets like Ireland, the United Kingdom, Germany and Australia, the company added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649624454","isCrawlerRequest":true}